logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Recordati Rare Diseases, Inc. drugs

    FiltersReset Filters
    7 results

    • chemet - succimer capsule

      (Succimer)
      Recordati Rare Diseases, Inc.

    • cystadrops

      (cysteamine hydrochloride)
      RECORDATI RARE DISEASES, INC.
      Usage: CYSTADROPS is a cystine-depleting agent used to treat corneal cystine crystal deposits in adults and children with cystinosis.

    • enjaymo

      (sutimlimab-jome)
      Recordati Rare Diseases, Inc.
      Usage: ENJAYMO (sutimlimab-jome) is indicated for the treatment of hemolysis in adults with cold agglutinin disease (CAD).

    • isturisa

      (Osilodrostat)
      Recordati Rare Diseases, Inc.
      Usage: ISTURISA is indicated for the treatment of adult patients with Cushing's disease when pituitary surgery is not viable or has not achieved a cure.

    • panhematin

      (hemin)
      Recordati Rare Diseases, Inc.
      Usage: PANHEMATIN is indicated for alleviating recurrent acute intermittent porphyria attacks linked to the menstrual cycle in women when carbohydrate therapy is insufficient. It aims to prevent severe attacks, but is not effective for repairing existing neuronal damage. Prior carbohydrate loading is recommended before administration.

    • signifor

      (pasireotide)
      Recordati Rare Diseases, Inc.
      Usage: SIGNIFOR is indicated for the treatment of adult patients with Cushing's disease who are not candidates for pituitary surgery or in cases where surgery has not been curative.

    • signifor lar

      (pasireotide)
      Recordati Rare Diseases, Inc.
      Usage: SIGNIFOR LAR is indicated for treating acromegaly in patients with inadequate surgical response or unsuitable for surgery, and for Cushing's disease when pituitary surgery is not an option or hasn't been curative.